Regulatory Effects of Zhenxin Formula in Treating Doxorubicin-Induced Heart Failure: Network Pharmacology and Animal Experimental Verification

Qiong Wu,1,* Hao Wang,2,* You Hua Wang,1 Jun Du,3 Bo Li,3 Xiao-Na Gan,3 Chen-Yang Liu,2 Jing Liang,2 Chang Liu,2 Min Cao2 1Department of Cardiology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 2Depa...

Full description

Saved in:
Bibliographic Details
Main Authors: Wu Q, Wang H, Wang YH, Du J, Li B, Gan XN, Liu CY, Liang J, Liu C, Cao M
Format: Article
Language:English
Published: Dove Medical Press 2025-07-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/regulatory-effects-of-zhenxin-formula-in-treating-doxorubicin-induced--peer-reviewed-fulltext-article-DDDT
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849320664275615744
author Wu Q
Wang H
Wang YH
Du J
Li B
Gan XN
Liu CY
Liang J
Liu C
Cao M
author_facet Wu Q
Wang H
Wang YH
Du J
Li B
Gan XN
Liu CY
Liang J
Liu C
Cao M
author_sort Wu Q
collection DOAJ
description Qiong Wu,1,* Hao Wang,2,* You Hua Wang,1 Jun Du,3 Bo Li,3 Xiao-Na Gan,3 Chen-Yang Liu,2 Jing Liang,2 Chang Liu,2 Min Cao2 1Department of Cardiology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 2Department of Emergency, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 3Nutrilite Health Institute, Amway (China) R&D Center, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Chang Liu, Department of Emergency, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Xunhui, 725 South Wan-Ping Road, Shanghai, 200032, People’s Republic of China, Tel +862164385700, Email doctorlchang@163.com Min Cao, Department of Emergency, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Xunhui, 725 South Wan-Ping Road, Shanghai, 200032, People’s Republic of China, Tel +862164385700, Email caomin_cm@163.comObjective: This study aimed to elucidate the mechanisms underlying the protective effects of Zhenxin Formula (ZXF) against doxorubicin (Dox)-induced HF through the integration of network pharmacology, phospho-antibody array analysis, and experimental validation.Methods: The active components and potential targets of ZXF were identified via the Traditional Chinese Medicine Systems Pharmacology (TCMSP) platform, while HF-associated target genes were retrieved from the OMIM, Genecards, and TTD databases. Protein-protein interaction (PPI) networks and compound-disease target networks were constructed using Cytoscape 3.7.2, with functional annotations performed through GO enrichment and KEGG pathway analyses using R software. Experimental validation involved the establishment of a Dox-induced HF model via intraperitoneal injection, with ZXF’s therapeutic effects evaluated using cardiac ultrasound, morphological staining, and Western blot analysis. Additionally, a phospho-antibody array was utilized to screen over 300 molecules across 16 canonical signaling pathways in ZXF-treated HF models, with Western blot analysis confirming the specific pathways implicated in ZXF’s therapeutic effects.Results: Network pharmacology analysis identified 56 potential active ingredients in ZXF, 47 of which were associated with HF-related targets. AKT1 emerged as the target most strongly correlated with HF improvement. In vivo, ZXF significantly enhanced cardiac function and mitigated myocardial fibrosis and cardiomyocyte apoptosis. Phospho-antibody array analysis revealed that 16 phosphorylated proteins were upregulated and 3 downregulated in the Dox-treated group. ZXF intervention resulted in the upregulation of 10 phosphorylated proteins and downregulation of 5. Comparative analysis highlighted PDK1-Phospho and FOXO1/3/4-Phospho as pivotal phosphorylated proteins mediating ZXF’s cardioprotective effects. Western blot analysis confirmed that ZXF enhanced phosphorylation levels of PI3K, PDK1, AKT, and FOXO1 in the Dox-induced HF model.Conclusion: This study, employing network pharmacology, phospho-antibody array analysis, and experimental validation, demonstrates that ZXF ameliorates cardiac dysfunction and suppresses myocardial apoptosis in Dox-induced HF through modulation of the PI3K/PDK1/AKT/FOXO1 signaling pathway.Keywords: network pharmacology, phospho-antibody array, Zhenxin Formula, heart failure, PI3K/PDK1/AKT/FOXO1 signaling pathway
format Article
id doaj-art-a99fbd3e8b2140839108faeeca857e4f
institution Kabale University
issn 1177-8881
language English
publishDate 2025-07-01
publisher Dove Medical Press
record_format Article
series Drug Design, Development and Therapy
spelling doaj-art-a99fbd3e8b2140839108faeeca857e4f2025-08-20T03:50:00ZengDove Medical PressDrug Design, Development and Therapy1177-88812025-07-01Volume 19Issue 159936008104772Regulatory Effects of Zhenxin Formula in Treating Doxorubicin-Induced Heart Failure: Network Pharmacology and Animal Experimental VerificationWu Q0Wang H1Wang YHDu J2Li B3Gan XNLiu CYLiang JLiu C4Cao M5cardiologyLonghua hospital Shanghai university of traditional Chinese MedicineNutrition Science & Product InnovationBotanic researchEmergencyEmergengcyQiong Wu,1,* Hao Wang,2,* You Hua Wang,1 Jun Du,3 Bo Li,3 Xiao-Na Gan,3 Chen-Yang Liu,2 Jing Liang,2 Chang Liu,2 Min Cao2 1Department of Cardiology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 2Department of Emergency, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 3Nutrilite Health Institute, Amway (China) R&D Center, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Chang Liu, Department of Emergency, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Xunhui, 725 South Wan-Ping Road, Shanghai, 200032, People’s Republic of China, Tel +862164385700, Email doctorlchang@163.com Min Cao, Department of Emergency, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Xunhui, 725 South Wan-Ping Road, Shanghai, 200032, People’s Republic of China, Tel +862164385700, Email caomin_cm@163.comObjective: This study aimed to elucidate the mechanisms underlying the protective effects of Zhenxin Formula (ZXF) against doxorubicin (Dox)-induced HF through the integration of network pharmacology, phospho-antibody array analysis, and experimental validation.Methods: The active components and potential targets of ZXF were identified via the Traditional Chinese Medicine Systems Pharmacology (TCMSP) platform, while HF-associated target genes were retrieved from the OMIM, Genecards, and TTD databases. Protein-protein interaction (PPI) networks and compound-disease target networks were constructed using Cytoscape 3.7.2, with functional annotations performed through GO enrichment and KEGG pathway analyses using R software. Experimental validation involved the establishment of a Dox-induced HF model via intraperitoneal injection, with ZXF’s therapeutic effects evaluated using cardiac ultrasound, morphological staining, and Western blot analysis. Additionally, a phospho-antibody array was utilized to screen over 300 molecules across 16 canonical signaling pathways in ZXF-treated HF models, with Western blot analysis confirming the specific pathways implicated in ZXF’s therapeutic effects.Results: Network pharmacology analysis identified 56 potential active ingredients in ZXF, 47 of which were associated with HF-related targets. AKT1 emerged as the target most strongly correlated with HF improvement. In vivo, ZXF significantly enhanced cardiac function and mitigated myocardial fibrosis and cardiomyocyte apoptosis. Phospho-antibody array analysis revealed that 16 phosphorylated proteins were upregulated and 3 downregulated in the Dox-treated group. ZXF intervention resulted in the upregulation of 10 phosphorylated proteins and downregulation of 5. Comparative analysis highlighted PDK1-Phospho and FOXO1/3/4-Phospho as pivotal phosphorylated proteins mediating ZXF’s cardioprotective effects. Western blot analysis confirmed that ZXF enhanced phosphorylation levels of PI3K, PDK1, AKT, and FOXO1 in the Dox-induced HF model.Conclusion: This study, employing network pharmacology, phospho-antibody array analysis, and experimental validation, demonstrates that ZXF ameliorates cardiac dysfunction and suppresses myocardial apoptosis in Dox-induced HF through modulation of the PI3K/PDK1/AKT/FOXO1 signaling pathway.Keywords: network pharmacology, phospho-antibody array, Zhenxin Formula, heart failure, PI3K/PDK1/AKT/FOXO1 signaling pathwayhttps://www.dovepress.com/regulatory-effects-of-zhenxin-formula-in-treating-doxorubicin-induced--peer-reviewed-fulltext-article-DDDTnetwork pharmacologyphospho-antibody arrayZhenxin Formulaheart failurePI3K/PDK1/AKT/FOXO1 signaling pathway
spellingShingle Wu Q
Wang H
Wang YH
Du J
Li B
Gan XN
Liu CY
Liang J
Liu C
Cao M
Regulatory Effects of Zhenxin Formula in Treating Doxorubicin-Induced Heart Failure: Network Pharmacology and Animal Experimental Verification
Drug Design, Development and Therapy
network pharmacology
phospho-antibody array
Zhenxin Formula
heart failure
PI3K/PDK1/AKT/FOXO1 signaling pathway
title Regulatory Effects of Zhenxin Formula in Treating Doxorubicin-Induced Heart Failure: Network Pharmacology and Animal Experimental Verification
title_full Regulatory Effects of Zhenxin Formula in Treating Doxorubicin-Induced Heart Failure: Network Pharmacology and Animal Experimental Verification
title_fullStr Regulatory Effects of Zhenxin Formula in Treating Doxorubicin-Induced Heart Failure: Network Pharmacology and Animal Experimental Verification
title_full_unstemmed Regulatory Effects of Zhenxin Formula in Treating Doxorubicin-Induced Heart Failure: Network Pharmacology and Animal Experimental Verification
title_short Regulatory Effects of Zhenxin Formula in Treating Doxorubicin-Induced Heart Failure: Network Pharmacology and Animal Experimental Verification
title_sort regulatory effects of zhenxin formula in treating doxorubicin induced heart failure network pharmacology and animal experimental verification
topic network pharmacology
phospho-antibody array
Zhenxin Formula
heart failure
PI3K/PDK1/AKT/FOXO1 signaling pathway
url https://www.dovepress.com/regulatory-effects-of-zhenxin-formula-in-treating-doxorubicin-induced--peer-reviewed-fulltext-article-DDDT
work_keys_str_mv AT wuq regulatoryeffectsofzhenxinformulaintreatingdoxorubicininducedheartfailurenetworkpharmacologyandanimalexperimentalverification
AT wangh regulatoryeffectsofzhenxinformulaintreatingdoxorubicininducedheartfailurenetworkpharmacologyandanimalexperimentalverification
AT wangyh regulatoryeffectsofzhenxinformulaintreatingdoxorubicininducedheartfailurenetworkpharmacologyandanimalexperimentalverification
AT duj regulatoryeffectsofzhenxinformulaintreatingdoxorubicininducedheartfailurenetworkpharmacologyandanimalexperimentalverification
AT lib regulatoryeffectsofzhenxinformulaintreatingdoxorubicininducedheartfailurenetworkpharmacologyandanimalexperimentalverification
AT ganxn regulatoryeffectsofzhenxinformulaintreatingdoxorubicininducedheartfailurenetworkpharmacologyandanimalexperimentalverification
AT liucy regulatoryeffectsofzhenxinformulaintreatingdoxorubicininducedheartfailurenetworkpharmacologyandanimalexperimentalverification
AT liangj regulatoryeffectsofzhenxinformulaintreatingdoxorubicininducedheartfailurenetworkpharmacologyandanimalexperimentalverification
AT liuc regulatoryeffectsofzhenxinformulaintreatingdoxorubicininducedheartfailurenetworkpharmacologyandanimalexperimentalverification
AT caom regulatoryeffectsofzhenxinformulaintreatingdoxorubicininducedheartfailurenetworkpharmacologyandanimalexperimentalverification